机译:贝伐单抗(Avastin® sup>)与兰尼单抗(Lucentis® sup>)治疗视网膜血管瘤增生的视觉和形态学结果
Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany;
Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany;
Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany;
Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany;
Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany;
Retinal angiomatous proliferations (RAP); Anti-VEGF; Bevacizumab (Avastin®); Ranibizumab (Lucentis®); Functional and morphological outcomes;
机译:贝伐单抗(Avastin?)与兰尼单抗(Lucentis?)治疗视网膜血管瘤增生的视觉和形态学结果。
机译:玻璃体内贝伐单抗与兰尼单抗治疗视网膜血管瘤增生
机译:雷尼单抗(Lucentis)与贝伐单抗(Avastin)治疗与年龄相关的黄斑变性:眼睛健康的经济差异
机译:快速和全面的五种版本的Bevacizumab -avastin与其生物仿制物的比较
机译:手术室微淋镜检查的功效,耐受性和安全性与良性声带病变的基于办事处的磷酸钾(KTP)激光治疗:多维语音结果的纵向前瞻性评估
机译:抗血管内皮生长因子治疗视网膜血管瘤增生后的预测因素和长期视觉结果
机译:玻璃体内贝伐单抗与兰尼单抗治疗视网膜血管瘤增生
机译:回顾medicare B部分avastin和Lucentis治疗老年性黄斑变性